Together, these results suggest that PROX1 plays a critical role in the anti-proliferative effect of rapamycin on HCC and that the upregulation of PROX1 by an MTOR inhibitor might be a useful molecular marker for predicting the efficacy of its anti-cancer effect on HCC cells. The gene discussed is MTOR; the disease is hepatocellular carcinoma.